Sei Investments Co. Buys 16,053 Shares of IDEAYA Biosciences, Inc. $IDYA

Sei Investments Co. increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 23.4% in the 1st quarter, Holdings Channel reports. The firm owned 84,760 shares of the company’s stock after purchasing an additional 16,053 shares during the period. Sei Investments Co.’s holdings in IDEAYA Biosciences were worth $2,825,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC grew its holdings in IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its stake in shares of IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter worth $61,000. Daiwa Securities Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares during the period. Finally, Fifth Third Bancorp acquired a new position in IDEAYA Biosciences in the 1st quarter valued at $84,000. Institutional investors own 98.29% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the transaction, the chief accounting officer directly owned 26,466 shares in the company, valued at $1,058,904.66. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IDYA has been the topic of several recent analyst reports. Guggenheim lifted their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Wall Street Zen raised IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. The Goldman Sachs Group raised their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, April 14th. Finally, Mizuho dropped their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Fourteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $50.12.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $37.02 on Friday. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of -19.08 and a beta of -0.10. The company’s fifty day moving average is $34.38 and its two-hundred day moving average is $32.68. IDEAYA Biosciences, Inc. has a 52-week low of $22.22 and a 52-week high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). The company had revenue of $8.86 million for the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm’s quarterly revenue was up 8800.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) EPS. As a group, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -4.36 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.